R C Hubbard

Summary

Affiliation: Pharmacia Corporation
Country: USA

Publications

  1. ncbi request reprint Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia
    R C Hubbard
    Pharmacia, 5200 Old Orchard Road, Skokie, IL 60077, USA
    Br J Anaesth 90:166-72. 2003
  2. ncbi request reprint Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
    A Karim
    Searle Research and Development, Skokie, Illinois 60077, USA
    J Rheumatol 26:2539-43. 1999
  3. ncbi request reprint A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects
    A Karim
    Pharmacia Research and Development, Skokie, Illinois 60077, USA
    J Clin Pharmacol 41:1111-9. 2001
  4. ncbi request reprint A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
    S E Daniels
    SCIREX Corporation, Austin, Texas, USA
    Clin Ther 23:1018-31. 2001
  5. ncbi request reprint The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively
    P J Desjardins
    SCIREX Corporation, Austin, Texas, USA
    Anesth Analg 93:721-7. 2001
  6. ncbi request reprint Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
    S I Harris
    SeaView Research, Miami, Florida, USA
    Clin Ther 23:1422-8. 2001
  7. ncbi request reprint The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain
    D R Mehlisch
    SCIREX, Austin, Texas, USA
    J Am Dent Assoc 135:1578-90. 2004
  8. ncbi request reprint Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
    G W Williams
    Division of Rheumatology, Scripps Clinic, La Jolla, California, USA
    Clin Ther 23:213-27. 2001
  9. ncbi request reprint Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
    J L Goldstein
    Section of Digestive and Liver Diseases, University of Illinois at Chicago, 60612-7323, USA
    Am J Gastroenterol 96:1019-27. 2001

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia
    R C Hubbard
    Pharmacia, 5200 Old Orchard Road, Skokie, IL 60077, USA
    Br J Anaesth 90:166-72. 2003
    ..This multicentre, double-blind, placebo-controlled study compared the opioid-sparing effectiveness and clinical safety of parecoxib sodium over 48 h, in 195 postoperative patients after routine total knee replacement surgery...
  2. ncbi request reprint Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
    A Karim
    Searle Research and Development, Skokie, Illinois 60077, USA
    J Rheumatol 26:2539-43. 1999
    ..To determine the effects of celecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2) on the renal clearance and plasma pharmacokinetic profile of stable methotrexate (MTX) doses in patients with rheumatoid arthritis (RA)...
  3. ncbi request reprint A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects
    A Karim
    Pharmacia Research and Development, Skokie, Illinois 60077, USA
    J Clin Pharmacol 41:1111-9. 2001
    ..All single i.m. doses up to the maximum of 40 mg of parecoxib, as well as concentrations of up to 20 mg/ml, were well tolerated...
  4. ncbi request reprint A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
    S E Daniels
    SCIREX Corporation, Austin, Texas, USA
    Clin Ther 23:1018-31. 2001
    ..05). All treatments were well tolerated. CONCLUSIONS: Parecoxib IV and IM provided effective analgesia. The 40-mg dose was comparable to ketorolac 60 mg on most measures of analgesia but had a longer duration of action...
  5. ncbi request reprint The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively
    P J Desjardins
    SCIREX Corporation, Austin, Texas, USA
    Anesth Analg 93:721-7. 2001
    ..These findings suggest that preoperative administration of parecoxib sodium, the injectable prodrug of the cyclooxygenase-2 specific inhibitor valdecoxib, is effective, safe, and well tolerated for treating postoperative pain...
  6. ncbi request reprint Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
    S I Harris
    SeaView Research, Miami, Florida, USA
    Clin Ther 23:1422-8. 2001
    ..CONCLUSION: These findings suggest that elderly patients may be at risk for GI ulceration even after short-term use of the conventional NSAIDs ketorolac and naproxen...
  7. ncbi request reprint The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain
    D R Mehlisch
    SCIREX, Austin, Texas, USA
    J Am Dent Assoc 135:1578-90. 2004
    ..v./i.m., administration is approved for postoperative pain in Europe, but not yet in the United States. However, previous trials in dental surgical patients have indicated that lower doses may be as effective...
  8. ncbi request reprint Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
    G W Williams
    Division of Rheumatology, Scripps Clinic, La Jolla, California, USA
    Clin Ther 23:213-27. 2001
    ..The availability of 2 effective regimens provides patients and physicians with increased flexibility in the selection of an appropriate dosing regimen for celecoxib therapy...
  9. ncbi request reprint Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
    J L Goldstein
    Section of Digestive and Liver Diseases, University of Illinois at Chicago, 60612-7323, USA
    Am J Gastroenterol 96:1019-27. 2001
    ....